Freshfields advised Novartis on its exclusive license agreement with Arvinas for a potential first-in-class prostate cancer treatment. Novartis, a global healthcare company, has entered into an...
You must be a Standard 1 Year member to access this content.
Freshfields advised Roivant on Sale of Telavant to Roche. Switzerland’s Roche (ROG.S) has entered into an agreement to pay an initial $7.1 billion to Roivant (ROIV.O)...
You must be a Standard 1 Year member to access this content.
Freshfields advised SERB Pharmaceuticals on its U.S. Partnership. SERB Pharmaceuticals, a global specialty pharmaceutical company, has acquired exclusive US rights to the ticagrelor reversal agent bentracimab...
You must be a Standard 1 Year member to access this content.
Freshfields advised Berkeley Lights on the deal, while Cravath represented IsoPlexis. Berkeley Lights (Nadsaq: BLI), a life sciences tools company, acquired IsoPlexis (Nasdaq: ISO), a company...
You must be a Standard 1 Year member to access this content.
Freshfields advised Sairopa on the deal. Sairopa, a clinical-stage company that develops novel treatments for cancer by modulating the patient’s immune system, signed a collaboration and...
You must be a Standard 1 Year member to access this content.
Freshfields advised Zymergen Inc. (Nasdaq: ZY) on the deal, while Ropes & Gray advised Ginkgo Bioworks. Zymergen Inc. (Nasdaq: ZY), a biotechnology company that uses a...
You must be a Standard 1 Year member to access this content.
Cuatrecasas and Paul, Weiss, Rifkind, Wharton & Garrison advised KPS Capital Partners on the deal. Leading global private equity firm, KPS Capital Partners, finalized the acquisition of the...
You must be a Standard 1 Year member to access this content.
CLP and Gómez-Acebo & Pombo advised Arendals Fossekompani ASA, while Cuatrecasas has advised the MET Group on the deal. Arendals Fossekompani has entered into an agreement with...
You must be a Standard 1 Year member to access this content.
